In postmenopausal women, SHBG appears to inhibit NAFLD-induced hepatocellular carcinoma (HCC) through regulation of estrogen activity and inhibition of lipogenesis (Lee et al., 2019). This evidence concerns the gene SHBG and metabolic dysfunction-associated steatotic liver disease.